<DOC>
	<DOCNO>NCT01183143</DOCNO>
	<brief_summary>This prospective , open-label , non-comparative , Phase IIIb trial ass convenience , safety efficacy new Gonal-F fbm [ recombinant follicle stimulate hormone ( r-FSH ) ] liquid formulation , common set ovulation induction ( OI ) also in-vitro fertilisation ( IVF ) .</brief_summary>
	<brief_title>Convenience Safety Assisted Reproductive Technology Procedures Using Gonal-F Filled Mass ( Fbm ) Liquid Formulation Applied Pen Ovulation Induction In-vitro Fertilization</brief_title>
	<detailed_description>Ovarian stimulation IVF intracytosolic sperm injection ( ICSI ) currently include suppression endogenous luteinising hormone ( LH ) suppression administration either gonadotropin release hormone ( GnRH ) agonist GnRH antagonist , follow stimulation multiple follicular development exogenous follicle stimulate hormone ( FSH ) administration . When adequate follicular development achieve , single human chorionic gonadotropin ( hCG ) dose administer mimic endogenic LH surge induce final oocyte maturation . In common setting , purpose ovarian stimulation obtain monofollicular development , ovulation induction first line treatment represent clomiphene . Follicle stimulate hormone gonadotropin indicate case clomiphene failure . OBJECTIVES - To assess , common setting , convenience , safety , efficacy protocol use Gonal-F fbm liquid formulation apply pen OI IVF/ICSI procedure . The study design primarily collect safety data related usage Gonal-F fbm liquid formulation , addition post treatment assessment convenience subject treat Gonal-F fbm . In OI intrauterine insemination ( IUI ) , objective ovarian stimulation monofollicular development initiation treatment take place first 7 day cycle . The initial daily dose Gonal-F 75-150 International Unit ( IU ) increase preferably 37.5 IU 50 IU 75 IU ( maximal dose exceed 225 IU ) 7 preferably 14 day interval necessary , obtain adequate excessive response . In IVF ICSI objective superovulation , multiple follicules development initiation treatment J2-J3 cycle start dose 150-225 IU . The study continue till confirmation pregnancy non pregnancy .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Female subject age 18 43 year Ambulatory subject Subjects willing get pregnant infertile , justifies ovarian stimulation treatment mono/paucifollicular development ( OI IUI ) multiple follicular development IVF/ICSI procedures Subjects able communicate well investigator comply requirement entire study Subjects give write informed consent , prior treatment Subjects enlarge ovary cyst unrelated polycystic ovary Subjects extrauterine pregnancy last 3 month Subjects several endometriosis ( Grade III &amp; IV ) Subjects history severe ovarian hyperstimulation syndrome Subjects history thromboembolic event Subjects malformative uterine pathology could disturb either implantation pregnancy processus Subjects premature menopause Subjects gynaecological bleed unknown origin Subjects ovarian , uterine , mammary cancer Subjects tumor hypothalamus pituitary gland Subjects history serious allergia , atopic asthma disease , Subjects know allergic reaction one FSH ingredient , On go pregnant , breast feeding subject Subjects participate trial last 3 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>43 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Infertility</keyword>
	<keyword>Ovulation induction</keyword>
	<keyword>Gonal-F</keyword>
	<keyword>Follitropin alpha</keyword>
	<keyword>Controlled ovarian stimulation .</keyword>
</DOC>